Abstract Library

#3050 Radioembolization for Neuroendocrine Liver Metastases: An Institutional Case Series, Systematic Review and Meta-Analysis

Introduction: Neuroendocrine liver metastases are clinically challenging and often non-resectable due to their frequent disseminated distribution. Radioembolisation with yttrium-90 labelled microspheres represents an emerging modality for NELM.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Clift A

Authors: Clift A, Frilling A, Braat A, Alsafi A, Wasan H,

Keywords: liver, metastases, radioembolization, yttrium, selective internal radiation therapy,

#2901 Data is Power - Registry Experience at an ENETS COE

Introduction: The collection of anonymised data for patients with neuroendocrine tumours is necessary for the ongoing improvement of patient care and research/clinical trials.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hogg A

Authors: Hogg A, Stell A, Marusic P, Sinnott R, Cummins M,

Keywords: PROMS, mobile phone app, registry,

#2746 Immunohistochemical Biomarker Expression in Gastro-Entero-Pancreatic Neuroendocrine Tumors at ENETS Centre of Excellence, University Hospital Zurich, Switzerland

Introduction: Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are a heterogeneous tumor entity with respect to biological behaviour and prognosis. This makes diagnosis and treatment a major challenge.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Siebenhüner A

Authors: Duschek S, Weber A, Curioni-Fontecedro A, Siebenhüner A,

Keywords: Biomarker, immunohistochemistry, GEP-NET, TMA, Prognosis, hormone receptor,

#2140 Neuroendocrine Neoplasms of the Appendix: Characterization of 251 Patients Referred to the Copenhagen NET Centre of Excellence

Introduction: Neuroendocrine neoplasms (NEN) of the appendix occur with an incidence of 0.15–0.6/100,000/year

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Holmager P, Willemoe G, Nielsen K, Groendahl V, Andreassen M,

Keywords: Appendiceal NEN, Relapse,

#2107 Carboplatin-Etoposide Chemotherapy (CB-ET) for Patients Diagnosed with Advanced Extra-Pulmonary (EP) Poorly Differentiated (PD) Neuroendocrine Carcinoma (NEC): Findings from a European Neuroendocrine Tumour Society Centre of Excellence

Introduction: Carboplatin-Etoposide is a first-line option for patients (pts) with advanced EP-PD-NEC. Data from randomised trials are lacking

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Frizziero M

Authors: Frizziero M, Lamarca A, Kordatou Z, Barriuso J, Nuttall C,

Keywords: carboplatin-etoposide, poorly-differentiated extra-pulmonary neuroendocrine carcinoma, activity, efficacy, safety,